Allogeneic Cell-Mediated Immunotherapy at the Stage of Minimal Residual Disease following High-Dose Chemotherapy Supported by Autologous Stem Cell Transplantation

Publisher： Karger

E-ISSN： 1421-9662|114|4|214-220

ISSN： 0001-5792

Source： Acta Haematologica, Vol.114, Iss.4, 2005-11, pp. : 214-220

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Is high-dose chemotherapy with autologous hematopoietic stem cell transplantation in breast cancer patients a done deal?

By Cheng Yee Chung   Ueno Naoto T  

Women's Health, Vol. 6, Iss. 4, 2010-07 ,pp. : 481-485

Future Medicine

Access to resources Recommend Favorite

High-Dose Chemotherapy and Autologous Hematopoietic Stem Cell Transplantation: The Lymphoma Experience and Its Potential Relevance to Solid Tumors

By  

Oncology, Vol. 58, Iss. 3, 2000-04 ,pp. : 198-206

Karger

Access to resources Recommend Favorite

Study of bone metabolism and angiogenesis in patients undergoing high‐dose chemotherapy/autologous hematopoietic stem cell transplantation

By  

EUROPEAN JOURNAL OF HAEMATOLOGY, Vol. 100, Iss. 2, 2018-02 ,pp. : 131-139

John Wiley & Sons Inc

Access to resources Recommend Favorite

High-Dose Therapy and Autologous Stem Cell Transplantation in Relapsed and Refractory Hodgkin’s Disease: Outcome Based on a Prognostic Model

By  

Acta Haematologica, Vol. 110, Iss. 4, 2003-12 ,pp. : 173-178

Karger

Access to resources Recommend Favorite

Outcomes of postchemotherapy retroperitoneal lymph node dissection following high‐dose chemotherapy with stem cell transplantation

By  

CANCER, Vol. 121, Iss. 24, 2015-12 ,pp. : 4369-4375

John Wiley & Sons Inc

Access to resources Recommend Favorite